gip/glp-1 receptor agonist Emerging Role of Dual GLP-1 and GIP Agonists | DMSO Dual and Triple Gut Peptide
Description
RothCLPerezFAWhitlockKBElfersCYanovskiJAShoemakerAHet alA phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity
It provides updated recommendations based on a modified Delphi process and supported by a systematic review of the current literature
Diabetes Atlas 10th edn (International Diabetes Federation, 2021)
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Baggio LL, Ussher JR, McLean BA, Cao X, Kabir MG, Mulvihill EE, Mighiu AS, Zhang H, Ludwig A, Seeley RJ, Heximer SP, Drucker DJ
HF, heart failure
